Abstract
Purpose: To provide the results of a prospective study evaluating PSMA-targeted 18F-DCFPyL PET/CT in patients with biochemical failure following radical prostatectomy for prostate cancer (PCa). Procedures: 31 patients with post-prostatectomy serum PSA levels ≥ 0.2 ng/mL and negative conventional imaging were enrolled in this study and imaged with 18F-DCFPyL PET/CT. A consensus central review identified foci of radiotracer uptake consistent with sites of PCa. Descriptive statistics were utilized. Results: 21/31 (67.7%) patients had at least one finding on 18F-DCFPyL PET/CT consistent with a site of PCa. Imaging was positive in 59.1% of patients with PSA < 1.0 ng/ml and in 88.9% of patients with PSA > 1.0 ng/mL. The median SUVmax across all lesions was 11.6 (range 1.5 to 57.6). Conclusion: In this prospective study utilizing the PSMA-targeted PET agent 18F-DCFPyL, most patients with biochemical failure following radical prostatectomy had foci of suspicious uptake, even at low serum PSA levels.
- Genitourinary
- Oncology: GU
- PET/CT
- Prostate-specific membrane antigen
- biochemical persistence
- biochemical recurrence
- Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.